|1.||Knoblach, Susan M: 3 articles (09/2005 - 03/2003)|
|2.||Cernak, Ibolja: 3 articles (09/2005 - 03/2003)|
|3.||Faden, Alan I: 3 articles (09/2005 - 03/2003)|
|4.||Asami, Yukihiro: 2 articles (06/2012 - 03/2009)|
|5.||Osada, Hiroyuki: 2 articles (06/2012 - 03/2009)|
|6.||Mathai, S: 2 articles (02/2009 - 11/2007)|
|7.||Zhang, R: 2 articles (02/2009 - 11/2007)|
|8.||Guan, J: 2 articles (02/2009 - 11/2007)|
|9.||Kozikowski, Alan P: 2 articles (03/2003 - 03/2003)|
|10.||Rubinstein, Pablo: 1 article (08/2015)|
|1.||Brain Injuries (Brain Injury)
03/01/2003 - "These studies confirm and extend the neuroprotective effects of this diketopiperazine in traumatic brain injury. "
03/01/2003 - "The authors developed a novel diketopiperazine that shows neuroprotective activity in a variety of in vitro models, as well as in a clinically relevant experimental model of traumatic brain injury (TBI) in rats. "
03/01/2003 - "Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo."
02/01/2009 - "Cyclo-L-glycyl-L-2-allylproline (NNZ-2591), a modified diketopiperazine, is neuroprotective and improves long-term function after hypoxic-ischaemic brain injury in rats. "
11/01/2007 - "Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats."
08/01/2015 - "The low molecular weight fraction of commercial 5% human serum albumin (LMWF5A) has been shown to have anti-inflammatory properties that are mediated, in part, by a diketopiperazine that is present in the albumin preparation and that was demonstrated to be safe and effective in reducing pain and improving function when administered intra-articularly in a phase III clinical trial. "
03/01/1987 - "Intracerebroventricular diketopiperazine (50 micrograms), a TRH metabolite, and RX77368 (50 micrograms), a TRH analogue, also potentiated swim (21 degrees C) analgesia, effects also independent of hypothermia and basal reactivity to pain. "
10/01/2014 - "Three naturally occurring oxyprenylated diketopiperazines were synthesized and preliminarily tested as growth inhibitory agents in vitro against various cancer cell lines. "
10/28/2011 - "Glionitrin B, a cancer invasion inhibitory diketopiperazine produced by microbial coculture."
09/01/1958 - "Negative data with thirty piperazinediones against recent isolates of mouse mammary tumors."
06/15/2012 - "Previously we reported the identification of a new oxepin-containing diketopiperazine-type marine fungal metabolite, named protuboxepin A which showed antiproliferative activity in several cancer cell lines. "
01/01/1980 - "ICRF-159 is a bis-diketopiperazine derivative active in a variety of preclinical animal tumor models. "
08/05/1997 - "The present study was designed to test the interaction between a nonantibody, nonpeptide, diketopiperazine-based inhibitor of PAI-1, XR5118, and PAI-1 and to assess the effect of XR5118 on PAI-1 activity in vitro and on in vivo thrombolysis and thrombus growth in an experimental thrombosis model in rabbits. "
|5.||Communicable Diseases (Infectious Diseases)
09/01/2004 - "The aim of this study was to determine if the diketopiperazines cyclo(L-histidyl-L-phenylalanyl) (cyclo(His-Phe)) and cyclo(L-histidyl-L-tyrosyl) (cyclo(His-Tyr)) have significant biological activity relevant to the treatment of cardiovascular-related disease states, cancer and infectious diseases. "
|4.||Plasminogen Activator Inhibitor 1
|10.||delta Opioid Receptors (delta Opioid Receptor)